(S021) Success of Prophylactic Single-Fraction Radiation Therapy in the Prevention of Pathologic Femoral Fractures

Publication
Article
OncologyOncology Vol 30 No 4_Suppl_1
Volume 30
Issue 4_Suppl_1

Single-fraction RT to the femur was effective in the prevention of femoral fractures. The pain score was also decreased in our patient population. Further studies are needed to explore 8 Gy/1 fx against standard radiation as a more effective means of delivering therapeutic and convenient treatment in metastatic patients.

Tijana Skrepnik, MD, Lauren Eisenberg, BS, Hitendra Patel, MD, Krisha Howell, MD; Department of Radiation Oncology, Department of Hematology/Oncology, Banner/University of Arizona Hospitals; University of Arizona

INTRODUCTION: Femoral metastases pose a threat of fracture. A low Mirel bone score (MBS) of < 8 points predicts a fracture rate of ~4% with standard fractionation radiation therapy (RT) alone. A score of > 8 points indicates a risk of fracture of 15% or higher, suggesting a role for surgical stabilization in addition to standard RT. Little data exist confirming the efficacy of single-fraction RT for fracture prevention.

METHODS: We performed a retrospective review of femoral metastases treated to 8 Gy × one fraction (fx). Relevant images and pain scores were reviewed for bony stability and assigned an MBS. Surgical consultation/intervention, prospectively acquired pain scores/toxicity assessments, and in-field fracture rates as reported on follow-up imaging were assessed.

RESULTS: In reviewing 198 charts, 24 metastatic femoral lesions from nonmyelomatous primaries were identified. Median clinical and radiographic follow-up was 1 month and 3 months, with a median overall survival status postcompletion of therapy of 4.3 months (range: 0.3–31.9 mo). The highest fracture risk region (peritrochanteric) constituted 41.7% of lesions, followed by head/neck (33.3%), femoral shaft (20.8%), and epiphyseal (4%) locations. Median MBS was 8 (range: 6–12), and two-thirds of patients did not receive a surgical consult. There were three fractures prior to RT (one nondisplaced, one previously stabilized, and one impending). Four sites received surgical intervention with a median intervention time of 14 months before RT (range: 0.4–24 mo). All (100%) irradiated bony sites had no subsequent fractures. Median pretreatment and posttreatment pain scores were 7 and 0, respectively, with a median improvement of 6 points on the pain scale.

CONCLUSION: Single-fraction RT to the femur was effective in the prevention of femoral fractures. The pain score was also decreased in our patient population. Further studies are needed to explore 8 Gy/1 fx against standard radiation as a more effective means of delivering therapeutic and convenient treatment in metastatic patients.

Proceedings of the 98th Annual Meeting of the American Radium Society - americanradiumsociety.org

Articles in this issue

(S002) A 15-Year Review of Radiation Therapy for Keloids at Two Institutions
(S003) Single-Fraction Radiation Therapy for the Treatment of Multiple Myeloma Bony Metastases Provides Pain Control and Decreases Time to Chemotherapy
(S001) Prognostic Value of Pretreatment Serum Inflammatory Markers in Patients Receiving Radiation Therapy for Oropharyngeal Cancer
(S004) Trend in Second Malignancy Risk for Head and Neck Cancer With Increased Utilization of IMRT: Analysis of SEER Database
(S005) Comparison of Legal Needs of a Group of Patients With Cancer: Economic and Geographic Factors
(S006) Mission Improvement: Lessons From Initiating a Resident-Led Quality Improvement Project on Smoking Cessation at a County Hospital
(S007) Results of a Phase II Trial Using Cetuximab Plus Docetaxel With Low-Dose Fractionated Radiation for Recurrent Unresectable Locally Advanced Head and Neck Carcinoma
(S008) The Effect of Simulation and Treatment Delays for Patients With Oropharyngeal Cancer Receiving Definitive Radiation Therapy in the Era of Risk Stratification Using Smoking and Human Papilloma Virus Status
(S009) Intensity-Modulated Radiation Therapy With Stereotactic Body Radiation Therapy Boost for Unfavorable Prostate Cancer: A Report on Three-Year Toxicity
(S011) Comparative Study Between Ileal Conduit and Indiana Pouch After Cystectomy for Patients With Carcinoma of Urinary Bladder
(S010) Computed Tomography–Assessed Measures of Bone Mineral Density and Muscle Mass as Predictors of Survival in Men With Prostate Cancer
(S012) Quantitative Imaging to Evaluate the Malignant Potential of Pancreatic Cysts
(S013) Spine Stereotactic Radiosurgery With Concurrent Tyrosine Kinase Inhibitors for Metastatic Renal Cell Carcinoma
(S014) The Impact of Radiation Therapy on Survival in Surgically Resected, High-Risk Patients With Ampullary Adenocarcinoma: A Population-Based Analysis
(S016) The Impact of Stereotactic Body Radiation Therapy on Overall Survival in Patients With Locally Advanced Pancreatic Cancer
Recent Videos
Harmonizing protocols across the health care system may bolster the feasibility of giving bispecifics to those with lymphoma in a community setting.
Although accuracy remains a focus in whole-body MRI testing in patients with Li-Fraumeni syndrome, comfortable testing experiences may ease anxiety.
Subsequent testing among patients in a prospective study may affirm the ability of cfDNA sequencing to detect cancers in those with Li-Fraumeni syndrome.
cfDNA sequencing may allow for more accessible, frequent, and sensitive testing compared with standard surveillance in Li-Fraumeni syndrome.
STX-478 showed efficacy in patients with advanced solid tumors regardless of whether they had kinase domain or helical PI3K mutations.
STX-478 may avoid adverse effects associated with prior PI3K inhibitors that lack selectivity for the mutated protein vs the wild-type protein.
Phase 1 data may show the possibility of rationally designing agents that can preferentially target PI3K mutations in solid tumors.
Funding a clinical trial to further assess liquid biopsy in patients with Li-Fraumeni syndrome may help with detecting cancers early across the board.
Michael J. Hall, MD, MS, FASCO, discusses the need to reduce barriers to care for those with Li-Fraumeni syndrome, including those who live in rural areas.
Related Content